


CellSeed Inc.

Fiscal 2020

First-Half Earnings Results

Presentation



Contents


- Company Profile
- Half-year financial summary FY 12/2020
- Earnings forecast
- About our COVID-19 response

CellSeed Inc. Corporate Information

Established May, 2001
Core competence Cell Sheet Engineering based on Temperature Responsive Polymers
Listed JASDAQ (7776) in 2010
Business

Regenerative Medical Products Business

- Commercialization of Cell Sheet Therapies



Regenerative Medicine Supporting Business

- Intelligent Culture Ware as Research Tools



UpCell®

- Contract Manufacturing Services • Consulting




CPC

“Cell Sheet Engineering”


Platform Technology of Regenerative Medicine

37°C Hydrophobic ⇔ 20°C Hydrophilic




Our Business Model


Mission
We take the initiative of contributing to global health care in the valuable and innovative field of regenerative medicine.



Development of Treatment Using Cell Sheet Engineering



Expansion of Cell Sheet Engineering



Contents

- Company Profile
- Half-year financial summary FY 12/2020
- Earnings forecast
- About our COVID-19 response

Half-year financial summary FY 12/2020


	First Half of the FY2020 Consolidated (January 2020 - June 2020)			First Half of the FY2019 Consolidated (January 2019 - June 2019)
	Amount (Millions of Yen)	Change (Millions of Yen)	Change from Previous Period (%)	Amount (Millions of Yen)
Net sales	58	-104	-64.1	162
Operating profit	-340	-19	—	-321
Ordinary profit	-341	-21	—	-320
Profit attributable to owners of parent	-340	-21	—	-319

- We were entrusted by Tokai University, which is a research partner, with the manufacturing of autologous chondrocyte sheets as the first product in advanced medicine.
- Thanks to the active sales promotion of devices, our domestic and overseas sales hit a record high (for the second quarter and the cumulative second quarter).
- The joint venture, which was established in Taiwan in Jan. 2020, plans to develop, produce, and sell products in the pipeline business other than the esophagus and cartilage.

Epithelial Cell Sheet for Esophageal Regeneration

(CLS2702C/D)

- A medical treatment developed by Tokyo Women's Medical University as a regenerative treatment for esophageal cancer (to heal esophageal wound and prevent stricture)
- Cell sheet is on a temperature-responsive cell culture ware and then transplanted into the ulcerated area in the esophagus after endoscopic surgery for esophageal cancer



- Clinical Research at Universities**

2008 – 2014 <Japan>

Tokyo Women's Medical Univ.	10case
Tokyo Women's Medical Univ. and Nagasaki Univ.	10case

<Europe>

Karolinska University Hospital	10case
--------------------------------	--------

Tokyo Women's Medical University

Basic Development Agreement



- Clinical Trials sponsored by CellSeed**

“SAKIGAKE Designation” in Feb. 2017

Japan



2017.4 Business alliance agreement signed with Taiwan's MetaTech(AP) Inc.

Taiwan (MetaTech)

Europe (Sweden)


- 2016 Submitted a notification of clinical trial plan
- 2019 1Q Completed the clinical trial in Japan
- 2020 4Q Planning to submit a notification of an additional clinical trial

- 2016 Consulted with European Medicines Agency (EMA)
- 2017 Licensed out the product to MetaTech in Taiwan
- 2018 Submitted a notification of a clinical trial in Taiwan
- 2020 Suspended the clinical trial in Europe

Chondrocyte Sheet

- Disease characteristics
 - Causes : ageing · obesity traumatic
 - No treatment to regenerate lost cartilage is available
- In Japan, estimated number of potential patients about 30 million persons of which, about 10 million shows symptoms.

変形性ひざ関節症の男女別-年齢別割合 (61~86歳、Grade II 以上)




Go Omori, Yoshio Koga and others From epidemiological survey for osteoarthritis of the knee


Autologous chondrocyte sheets

Started medial treatment in Tokai University as Advanced Medicine B



- Collect Autologous Cartilage Cells



- Manufacture Cell Sheet



- Transplant to Patient



chondrocyte sheets

Indications : Knee Osteoarthritis

Overview of Chondrocyte Sheet Project


Started medial treatment in Tokai University as Advanced Medicine B



- < **Autologous Cells** >
 - 2019/1
approved by the MHLW in the 71st Conference on Advanced Medicine
 - 2020/8
Completed the operation on the first patient for Advanced Medicine B.
- < **Allogeneic Cells** >
 - 2019/12
completed transplants of 10 cases

- Licensing out Autologous cell sheet to MetaTech in Taiwan
 - Commercialization of Allogeneic Chondrocyte Sheet Product
- 

Allogeneic chondrocyte sheets



- **Clinical Research at Tokai University**
 - Completed in December 2019 transplants of 10 cases
 - selected for the 2018 Project Focused on Developing Key Evaluation Technology: Acceleration of Developing Regenerative Medicine Technology Seeds (for 3 years, from October 2018 to March 2021.)
- **CellSeed worked on the development of cell banks and the automation of cell sheets production.**

CellSeed Temperature Sensitive Cell Cultureware Lineup

UpCell® Cell Sheet Recovery (Temperature Sensitive)	RepCell™ Cell Recovery (Temperature Sensitive)	HydroCell™ Ultra-Low Adhesion Cell Cultureware
<ul style="list-style-type: none">● Temperature-responsive cell cultureware for "Cell Sheet" engineering	<ul style="list-style-type: none">● Temperature-responsive cell cultureware for cell collection	<ul style="list-style-type: none">● Low cell binding cultureware
	 <p>3 x 3 mm Grid Wall</p>	

Sales of equipment and materials were healthy in domestic and abroad.

- MiCAN Technologies Inc., which develops and sells cells for researching infectious diseases caused by the novel coronavirus, etc., has adopted HydroCell™, a cell cultureware of our company.
- Thanks to the enhanced cooperation with existing agencies and active sales promotion, domestic and overseas sales hit a record high (for the second quarter and the cumulative second quarter).
- Especially, the overseas sales of UpCell® has been growing steeply as last year.
- The sales of devices to the alliance partner MetaTech are healthy.

Supplying cell cultureware equipment to a company developing cells for research on Novel coronavirus



MiCAN Technologies Inc., our client, develops cells for researching various infectious diseases, including the novel coronavirus, and immune disorders, and has adopted HydroCell™, a cell cultureware of our company, for their development process.

Their project for “Developing Cells for ADE Evaluation, Etc. for the Development of Vaccines against the Novel Coronavirus” was selected as a “Project for Technological Development against the Infectious Diseases Caused by Viruses, Etc.” offered by AMED.

◆ MiCAN Technologies Inc. Company Profile

Access	KKVP, 1-36 Goryo-ohara, Nishikyo-ku, Kyoto 615-8245 Japan
Business	Development and sale of blood cell-like products for research based on technologies for regenerative medicine
Establishment of company	Investee of OUVC No.1 Fund operated by the Osaka University Venture Capital
President CEO	Kazuo Miyazaki M.S., MBA
URL	https://www.micantechnologies.com/home-2

Regenerative Medicine Supporting Business

1. Regenerative Cell Sheet Product Manufacture Method Development, Consigned Manufacture	2. Facility Management, Application Submission Support	3. Cell Culturing Technician Training
<ul style="list-style-type: none">■ Consigned manufacture■ Manufacture method development■ Quality testing <p><Characteristics></p> <ul style="list-style-type: none">• Cell sheet manufacturing using UpCell®• Certified facility for specific cell processing (FA3160008)• Japanese Society for Regenerative Medicine Certified Clinical Culturing Specialist, including large number of staff with bountiful experience and knowledge of culturing technologies	<ul style="list-style-type: none">■ Support for certification application, notification for specific cell processing■ Document creation for procedural manual, standard handbook, others consulting■ Cell processing center facilities, support management structure, maintenance provision■ Application document creation, others	<ul style="list-style-type: none">■ Cell sheet culturing training■ Cell sheet peeling training, others



To prevent coronavirus infection, we adjourned The 2nd Cell Sheet Engineering Innovation Forum scheduled to be held in October 15 2020.

We will contact you as soon as that forum date has been decided.



第2回細胞シート工学イノベーションフォーラム
The 2nd Cell Sheet Engineering Innovation Forum

～細胞シートの未来を語ろう!～

2020年10月15日(木)
13:30～(受付12:00～) 懇親会18:00～

science bar INCUBATOR
出張出張

会場:日本科学未来館 7階
定員:200名(事前登録制、先着順)
参加費・懇親会費:アカデミアの方:無料
企業の方:3,000円

※会費は事前申込となります。
※日本科学未来館の常設展の入場は別途料金が必要です。

講演者

清水 達也
東京女子医科大学 先端生命医科学研究所 所長、教授

宮原 裕二
東京医科歯科大学 生体材料工学研究所 所長、助研

崎山 亮一
大阪工業大学 工学部生命工学科 准教授

西田 幸二
大阪大学大学院 医学系研究科 主任教授

※講演者については変更される可能性があります。

CellSeed
Regenerate the Future

ポスター
演題募集

テーマ 「細胞シート」、「温度応答性細胞培養器材」及び周辺技術に関する研究

最優秀賞 30万円×1名
優秀賞 5万円×4名
奨励賞 1万円×数名

※賞額に募集要項がごさいます。最優秀賞候補の方には当日受賞公演(15分)を行っていただきます。

旅費支援 関東圏外の方: 交通費全額+宿泊費一律1万円
関東圏内の方: 交通費のみ一律2千円

※旅費支援はポスター発表に採択された方が対象となります。

Contents

- Company Profile
- Half-year financial summary FY 12/2020
- Earnings forecast
- About our COVID-19 response

Revisions to Full-Year Consolidated financial estimation for FY 12/2020

Due to the pandemic of the novel coronavirus, the comprehensive development support for the joint venture established in Taiwan in Jan. 2020 was delayed, and our activities for forming business alliances and licensing in Asian countries, such as China and Taiwan, were delayed. Due to these effects, it is difficult to reasonably calculate the full-year consolidated financial estimates, which was announced on Feb. 14, 2020, so it is still to be determined.

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of parent
FY2020 Forecast (As of February 14, 2020)	310	-1,020	-1,020	-1,020
FY2020 Forecast (As of July 16, 2020)	—	—	—	—


Contents

- Company Profile
- Half-year financial summary FY 12/2020
- Earnings forecast
- About our COVID-19 response

Our response to Novel coronaviruses

Since Feb. 27, 2020, our company has promoted employees to work from home, and as disclosed on Aug. 3, 2020, we will continue telework until Sep. 30, 2020.

From now on, we will promote diverse workstyles according to the environment of each employee, including the combination of telework and work in the office.





This presentation is made by CellSeed Inc. solely for the disclosure of the financial statements, and not published for the purpose of soliciting sales or purchases of securities in Japan and any other regions.